Sandoz Group AG Reports Strong Financial Results for First Half of 2025

Sandoz Group AG, a leading pharmaceutical company, has announced its financial results for the first half of 2025. Key highlights from the report include:

• Sales growth accelerated in the second quarter, driven by a 12% increase in biosimilars sales.
• Biosimilars now account for 30% of Q2 net sales, representing a significant increase in the segment.
• The company’s core EBITDA margin improved to 20.0%.

The company’s performance was driven by its global presence and diversified product portfolio, despite challenges in the US market. Sandoz’s stock price has shown a moderate increase, reflecting the positive sentiment towards the company’s financial results.

Key Financial Highlights

• Sales growth in the second quarter: 12% increase in biosimilars sales
• Biosimilars segment: 30% of Q2 net sales
• Core EBITDA margin: 20.0%

Market Performance

• Sandoz’s stock price has shown a moderate increase, reflecting the positive sentiment towards the company’s financial results.